Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines in neuroscience and oncology. The company has a current market capitalization of $8.63 billion and a stock price of $142.02 as of the latest data.
| Inputs | |
|---|---|
| EPS | $8.64 |
| Median historical P/E | 17.44 |
| Expected growth rate | 12.05% |
| Margin of Safety | 25.00% |
| Conservative growth rate | 8.00% |
| Discount rate | 9.00% |
| Calculations | |
|---|---|
| Year | EPS*Growth rate |
| 1 | $9.33 |
| 2 | $10.08 |
| 3 | $10.88 |
| 4 | $11.75 |
| 5 | $12.69 |
| Value in 5 years | $221.32 |
| Present value | $143.65 |
| Intrinsic value with MoS | $107.74 |
| Inputs | |
|---|---|
| Cash & Cash Equivalents | $2.99B |
| Total Liabilities | $6.17B |
| Free cash flow | $1.43B |
| Shares outstanding | 60.73M |
| Expected growth rate | 5.43% |
| Margin of Safety | 25.00% |
| Conservative growth rate | 4.00% |
| Growth decline rate | 5.00% |
| Discount rate | 9.00% |
| Year 10 FCF multiplier | 12 |
| Calculations | ||
|---|---|---|
| Year | FCF * Growth rate | NPV FCF |
| 1 | $1.49B | $1.36B |
| 2 | $1.54B | $1.30B |
| 3 | $1.61B | $1.24B |
| 4 | $1.67B | $1.18B |
| 5 | $1.74B | $1.13B |
| 6 | $1.81B | $1.08B |
| 7 | $1.88B | $1.03B |
| 8 | $1.96B | $0.98B |
| 9 | $2.04B | $0.94B |
| 10 | $2.12B | $0.89B |
| Total NPV FCF | $11.14B |
| Year 10 FCF value | $10.67B |
| Cash & Equivalents | $2.99B |
| Total Liabilities | $6.17B |
| Company value: | $18.63B |
| Per Share value: | $306.72 |
| Intrinsic value with MoS: | $230.04 |
Jazz Pharmaceuticals has a debt-to-equity ratio of 150.64%, which means the company has approximately $1.51 of debt for every $1 of equity. This warrants a closer analysis in the context of the company's financial health and industry positioning.
For pharmaceutical companies, a debt-to-equity ratio of 150.64% is relatively high but not uncommon. The pharmaceutical industry often requires substantial capital investments for research and development, clinical trials, acquisitions, and commercialization activities.
While Jazz Pharmaceuticals' debt-to-equity ratio of 150.64% indicates higher-than-average leverage, the company's strong cash flow generation, substantial cash reserves, and healthy profitability metrics suggest that this debt level is manageable. The company appears to be using debt strategically to finance growth rather than compensating for operational weaknesses.
For investors, it would be prudent to monitor how effectively Jazz deploys this capital and whether it translates to returns that exceed the cost of servicing the debt. The company's stable business model and growth prospects provide reasonable assurance that the current debt level, though elevated, does not pose an immediate concern to the company's financial health.
Based on our analysis, Jazz Pharmaceuticals (JAZZ) appears to be undervalued according to both valuation methods:
The current market price of $142.02 is above our conservative P/E-based valuation but significantly below our DCF-based valuation. This suggests that:
The divergence between these two valuation methods suggests that investors may be focusing more on near-term earnings multiples rather than the long-term cash flow generating capability of the company. With strong projected earnings growth (12.05% for the current year) and robust free cash flow, Jazz Pharmaceuticals shows potential for long-term value creation.
Analysts have a consensus price target of $193.58, which is between our two valuation estimates and represents a potential upside of about 36% from the current price.
When considering the debt analysis alongside valuation metrics, Jazz Pharmaceuticals presents a mixed but generally positive investment case. The higher debt level is balanced by strong cash reserves and robust cash flow generation, supporting the company's growth initiatives without presenting immediate financial risks.